Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis

Yoshimine,Yozo; Uto,Hirofumi; Kumagai,Kotaro; Mawatari,Seiichi; Arima,Shiho; Ibusuki,Rie; Mera,Kumiko; Nosaki,Tsuyoshi; Kanmura,Shuji; Numata,Masatsugu; Tamai,Tsutomu; Moriuchi,Akihiro; Tsubouchi,Hirohito; Ido,Akio

doi:10.3892/or.2015.3745

Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis

Authors:
- Yozo Yoshimine
- Hirofumi Uto
- Kotaro Kumagai
- Seiichi Mawatari
- Shiho Arima
- Rie Ibusuki
- Kumiko Mera
- Tsuyoshi Nosaki
- Shuji Kanmura
- Masatsugu Numata
- Tsutomu Tamai
- Akihiro Moriuchi
- Hirohito Tsubouchi
- Akio Ido
View Affiliations

Affiliations: Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Department of HGF Tissue Repair and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
Published online on: January 21, 2015 https://doi.org/10.3892/or.2015.3745
Pages: 1657-1666

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The molecular mechanisms underlying the progression of nonalcoholic steatohepatitis (NASH) have not been fully elucidated. The aim of this study was to identify factors involved in NASH progression by analysis of pathophysiological features and gene-expression profiles in livers of STAM mice, a model of NASH-associated hepatocarcinogenesis. C57BL/6N (B6N) mice were injected with streptozotocin to generate STAM mice. Four-week-old male STAM and B6N mice were fed a high-fat diet (HFD) (STAM-F, B6N-F) or a conventional diet (STAM-C, B6N-C) until they were 10, 14, or 18 weeks old. Blood glucose and nonalcoholic fatty liver disease (NAFLD) activity scores of STAM-F were higher than those of STAM-C during all observation periods. STAM-F mice had more severe hepatic fibrosis at 14 weeks, and exhibited higher levels of α-fetoprotein-positive hepatic tumor formation with multiplication than STAM-C mice at 18 weeks. At 14 weeks, cDNA microarray analysis revealed that the hepatic expression of eight mRNAs was ≥30-fold higher in STAM-F than B6N-F mice. The expression of another four genes was increased ≥5-fold in STAM-F than B6N-F mice, and ≥5-fold in B6N-F relative to B6N-C mice. Of the 12 genes, the difference in Sptlc3 mRNA expression was most pronounced, and gradually increased over time, as determined by quantitative RT-PCR in STAM-F mice. In addition, Sptlc3 mRNA expression in STAM-F mice was higher than that in db/db mice that received HFD and in B6N mice fed a choline‑deficient L-amino acid (CDAA)-defined diet. In conclusion, a high-fat diet aggravated pathophysiological findings in the liver in NASH mouse models, and the hepatic expression of Sptlc3 mRNA was potentially associated with NASH progression.

View Figures

View References

1	Ludwig J, Viggiano TR, McGill DB and Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:434–438. 1980.PubMed/NCBI
2	Andy SY and Keeffe EB: Nonalcoholic fatty liver disease. Rev Gastrointest Disord. 2:11–19. 2002.
3	Angulo P and Lindor KD: Non-alcoholic fatty liver disease Quadrennial review. J Gastroenterol Hepatol. 17:S186–S190. 2002. View Article : Google Scholar
4	White DL, Kanwal F and El-Serag HB: Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 10:1342–1359. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M and Kudo M: Report of the 17th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 37:676–691. 2007. View Article : Google Scholar : PubMed/NCBI
6	Day CP and James OF: Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
7	Tilg H and Moschen AR: Evolution of inflammation in nonal-coholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 52:1836–1846. 2010. View Article : Google Scholar : PubMed/NCBI
8	Anstee QM and Goldin RD: Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 87:1–16. 2006. View Article : Google Scholar : PubMed/NCBI
9	Denda A, Kitayama W, Kishida H, Murata N, Tsutsumi M, Tsujiuchi T, Nakae D and Konishi Y: Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res. 93:125–132. 2002. View Article : Google Scholar : PubMed/NCBI
10	Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H and Yoneyama H: A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 46:141–152. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, Mccullough AJ and Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research N. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
12	Renehan A, Smith U and Kirkman MS: Linking diabetes and cancer: a consensus on complexity. Lancet. 375:2201–2202. 2010. View Article : Google Scholar : PubMed/NCBI
13	Rosmorduc O and Fartoux L: HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol. 36:202–208. 2012. View Article : Google Scholar : PubMed/NCBI
14	Shimizu M, Tanaka T and Moriwaki H: Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemo-prevention of liver carcinogenesis. Semin Immunopathol. 35:191–202. 2013. View Article : Google Scholar
15	Morss AS and Edelman ER: Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem. 282:14635–14644. 2007. View Article : Google Scholar : PubMed/NCBI
16	Niwa Y, Matsumura M, Shiratori Y, Imamura M, Kato N, Shiina S, Okudaira T, Ikeda Y, Inoue T and Omata M: Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Hepatology. 23:1384–1392. 1996.PubMed/NCBI
17	Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL and Chen J: Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 12:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
18	Satoh K, Takahashi G, Miura T, Hayakari M and Hatayama I: Enzymatic detection of precursor cell populations of preneoplastic foci positive for gamma-glutamyltranspeptidase in rat liver. Int J Cancer. 115:711–716. 2005. View Article : Google Scholar : PubMed/NCBI
19	Shin E, Ryu HS, Kim SH, Jung H, Jang JJ and Lee K: The clinicopathological significance of heat shock protein 70 and glutamine synthetase expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 18:544–550. 2011. View Article : Google Scholar : PubMed/NCBI
20	Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P and Belghiti J: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 49:851–859. 2009. View Article : Google Scholar
21	Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ and Ting JP: Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 12:408–415. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hanada K: Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta. 1632:16–30. 2003. View Article : Google Scholar : PubMed/NCBI
23	Menaldino DS, Bushnev A, Sun A, Liotta DC, Symolon H, Desai K, Dillehay DL, Peng Q, Wang E, Allegood J, Trotman-Pruett S, Sullards MC and Merrill AH Jr: Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. Pharmacol Res. 47:373–381. 2003. View Article : Google Scholar : PubMed/NCBI
24	Hornemann T, Richard S, Rütti MF, Wei Y and Von Eckardstein A: Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase. J Biol Chem. 281:37275–37281. 2006. View Article : Google Scholar : PubMed/NCBI
25	Hornemann T, Wei Y and Von Eckardstein A: Is the mammalian serine palmitoyltransferase a high-molecular-mass complex? Biochem J. 405:157–164. 2007.PubMed/NCBI
26	Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhya B, Harvey-White J and Kunos G: Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology. 59:143–153. 2014. View Article : Google Scholar
27	Ussher JR, Koves TR, Cadete VJ, Zhang L, Jaswal JS, Swyrd SJ, Lopaschuk DG, Proctor SD, Keung W, Muoio DM and Lopaschuk GD: Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes. 59:2453–2464. 2010. View Article : Google Scholar : PubMed/NCBI
28	Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H and de La Monte SM: Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis. 16:715–729. 2009.PubMed/NCBI
29	Promrat K, Longato L, Wands JR and De La Monte SM: Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res. 41:754–762. 2011. View Article : Google Scholar : PubMed/NCBI
30	Kurek K, Wiesiolek-Kurek P, Piotrowska DM, Lukaszuk B, Chabowski A and Zendzianendzian-Piotrowska M: Inhibition of ceramide de novo synthesis with myriocin affects lipid metabolism in the liver of rats with streptozotocin-induced type 1 diabetes. Biomed Res Int. 2014:9808152014. View Article : Google Scholar : PubMed/NCBI
31	Lee YS, Choi KM, Choi MH, Ji SY, Lee S, Sin DM, Oh KW, Lee YM, Hong JT, Yun YP and Yoo HS: Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G(2)/M phase arrest. Cell Prolif. 44:320–329. 2011. View Article : Google Scholar : PubMed/NCBI
32	Lee YS, Choi KM, Lee S, Sin DM, Lim Y, Lee YM, Hong JT, Yun YP and Yoo HS: Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis. Cancer Biol Ther. 13:92–100. 2012. View Article : Google Scholar
33	Greenbaum CJ: Insulin resistance in type 1 diabetes. Diab Metab Res Rev. 18:192–200. 2002. View Article : Google Scholar
34	Bulum T, Kolaric B, Duvnjak L and Duvnjak M: Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci. 56:3655–3663. 2011. View Article : Google Scholar : PubMed/NCBI
35	Regnell SE and Lernmark A: Hepatic steatosis in type 1 diabetes. Rev Diab Stud. 8:454–467. 2011. View Article : Google Scholar